Stayble is developing an injectable treatment against chronic low back pain triggered by disc degeneration. A condition that today is ranked as one of the costliest medical condition in the western hemisphere with a yearly cost in US alone of over $40 billion.
Stayble’s treatment has the potential to offer an alternative to the millions of people who does not respond to analgesics and physiotherapy, and who are not eligible, cannot afford, or do not want to take the chance with a spinal fusion.
Stayble is currently initiating its first clinical trial.
Andreas Gerward, VD, +46730 808 397, firstname.lastname@example.org